Companies › Zhejiang Doer Biologics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Gastroenterology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DR10624 Injection | – | Phase 2 | MASLD | – |
| DR30206 Monoclonal antibody targeting gastrointestinal cancer | – | Phase 1 | Gastrointestinal Cancer; Solid Tumor | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07024212 | DR10624 Injection | Phase 2 | MASLD | Gastroenterology | Jun 2026 |
| NCT07056777 | DR30206 | Phase 1 | Gastrointestinal Cancer | Oncology | Apr 2027 |
| NCT06132828 | DR30206 | Phase 1 | Solid Tumor | Oncology | Jul 2027 |
No annotated target.
–
Institut de Recherches Internationales Servier (I.R.I.S.) Hinova Pharmaceuticals Beijing Sungen Biomedical Technology HighField Biopharmaceuticals Onconic Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.